Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Mar 6, 2017 (10 years ago)

ATENOLOL Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Presence of Foreign Tablets/Capsules: Customer complaint that a bottle of atenolol 50 mg Tablets USP contained a paroxetine 20 mg tablet.

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

ATENOLOL Tablets, USP, 50 mg, packaged in a) 100-count bottles (NDC 68382-023-01) and b) 1000-count bottles (NDC 68382-023-10), Rx only, Manufactured by: Cadila Healthcare Ltd., India; Distributed by: Zydus Pharmaceuticals USA Inc., Pennington, NJ 08534.

Affected NDCs 68382-0023-01 68382-0023-10

Compare with the code on your package — it is the most precise check available.

Drug: Atenolol Category: Blood Pressure Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Atenolol
NDC 68382-0023
50 mg/1 Tablet
Oral
Zydus Pharmaceuticals USA Inc. Rx
Recalling firm
Zydus Pharmaceuticals USA Inc
NDC code
68382-023-01
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0605-2017 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Atenolol recalls

See all
Class I · High risk

Atenolol Tablets

Label Mix - up; a bottle labeled as Atenolol 25mg Tablets contained Clopidogrel 75mg Tablets

Terminated Labeling / mix-up Golden State Medical Supply Inc. NDC 60429-027-10 D-0019-2023
Class II · Moderate risk

ATENOLOL Tablets

Presence of Foreign Tablets/Capsules: Customer complaint that a bottle of atenolol 50 mg Tablets USP contained a paroxetine 20 mg tablet.

Terminated Particulate / foreign matter Legacy Pharmaceutical Packaging LLC NDC 68645-493-54 D-0606-2017
Class II · Moderate risk

ZyGenerics ATENOLOL Tablets

Superpotent Drug: A complaint was reported by a pharmacist who stated several tablets were noticeably thicker in appearance.

Terminated Wrong potency / content Zydus Pharmaceuticals USA Inc NDC 68382-022-01 D-0007-2015
Class II · Moderate risk

ATENOLOL Tablet

Labeling:Label Mixup; ATENOLOL, Tablet, 12.5 mg (1/2 of 25 mg) may be potentially mislabeled as VITAMIN B COMPLEX WITH C/FOLIC ACID, Tablet, NDC 60258016001, Pedigree: AD73652_19, EXP: 5/30/2014; PIROXICAM, Capsule, 10 mg, NDC 00093075601, Pedigree: AD21836_1, EXP: 3/31/2014.

Terminated Labeling / mix-up Aidapak Services, LLC D-679-2014

Other recalls by Zydus Pharmaceuticals USA Inc

All 2017 recalls
Class II · Moderate risk

Erythromycin Tablets

CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit

Ongoing Nitrosamine impurity Zydus Pharmaceuticals (USA) Inc NDC 70710-1048-3 D-0545-2026
Class II · Moderate risk

Erythromycin Tablets

CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit

Ongoing Nitrosamine impurity Zydus Pharmaceuticals (USA) Inc NDC 70710-1047-3 D-0544-2026
Class II · Moderate risk

Icosapent Ethyl Capsules

Failed Tablet/Capsule specifications: Red dots inside capsule and melted capsule caused by oxidized Icosapent ethyl, the active ingredient.

Ongoing Failed specification Zydus Pharmaceuticals (USA) Inc D-0400-2026